Fulcrum Therapeutics, Inc. (FULC) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.67

From 52W high−74.66%

Volume1.19M

Market cap$282.61M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$3.67

From 52W high

−74.66%

Volume

1.19M

Market cap

$282.61M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.4x

P/E (TTM)

—

RSI (14)

45.8

MomentumView details →

1D Return

+1.37%

YTD Return

−67.28%

SummaryUpdated Jun 1, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in July 2019 and focuses on developing treatments for genetically defined rare diseases with high unmet medical need. Fulcrum has evolved from pursuing multiple therapeutic programs to concentrating primarily on <b>pociredir</b> for sickle cell disease, following the discontinuation of its lead program <b>losmapimod</b> for facioscapulohumeral muscular dystrophy (FSHD) in 2024 after Phase 3 trial results failed to meet endpoints.

Ask drillr about Fulcrum Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−27.36%

ROA (TTM)

−26.24%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+0.82%

FCF YoY

−1.41%

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

—

EBITDA YoY

−5.92%

MomentumView details →

1D Return

+1.37%

YTD Return

−67.28%

1Y Return

−59.87%

RSI (14)

45.8

vs 50D SMA

−2.00%

vs 200D SMA

−39.89%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

31.35x

Quick Ratio

31.35x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.21

EPS Surprise

13.69%

Beats (12Q)

8/12

Next Q EPS Est

−$0.05

Avg Surprise (4Q)

6.54%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−85.00M

Op. CF (TTM)

−65.78M

Next earningsOct 29, 2026 →

Latest newsMore news →

Kaplan Fox & Kilsheimer LLP announced that it is investigating potential securities violations by Fulcrum Therapeutics, Inc.13d ago

Kaplan Fox & Kilsheimer LLP announced on October 2, 2026 that it is investigating Fulcrum Therapeutics, Inc. for possible securities law violations.17d ago

Similar companies

Surrozen, Inc.SRZN Contineum Therapeutics, Inc. Class A Common StockCTNM Agenus Inc.AGEN Shanghai Bio-heart Biological Technology Co., Ltd.02185.HK Artiva Biotherapeutics, Inc.ARTV ProKidney Corp.PROK Find similar companies →

Latest newsMore news →

Kaplan Fox & Kilsheimer LLP announced that it is investigating potential securities violations by Fulcrum Therapeutics, Inc.13d ago Kaplan Fox & Kilsheimer LLP announced on October 2, 2026 that it is investigating Fulcrum Therapeutics, Inc. for possible securities law violations.17d ago Kaplan Fox & Kilsheimer LLP broadened its investigation into potential securities law violations by Fulcrum Therapeutics, Inc.27d ago